Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC). Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of
Anlotinib with Camrelizumab in Lung Cancer Treatment Background Checkpoint inhibitors (CPIs) and anti-angiogenic agents are emerging as potential novel treatment choices for advanced cancers including metastatic non-small-cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatment of patients with advanced NSCLC.
Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT Inoperable locally advanced non-small cell lung cancer (NSCLC): An Introduction Accounting for approximately 80% of lung cancers, non-small cell lung cancer (NSCLC) is the most common subtype. Most NSCLC patients are diagnosed at an advanced stage with a mere 15-20%